References
- Stone R.M., Mayer R.J. The unique aspects of acute promyelocytic leukemia. J. Clin. Oncol 1990; 8: 1913–21
- Warrell R.P., Jr., de The H., Wang Z.-Y., Degos L. Acute promyelocytic leukemia. N. Engl. J. Med. 1993; 329: 177–89
- Rodeghiero F., Avvisati G., Castaman G., Barbui T., Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 1990; 75: 2112–7
- Bernard J., Weil M., Boiron M., Jacquillat C., Flandrin G., Gemon M.-F. Acute promyelocytic leukemia: Results of treatment by daunorubicin. Blood 1973; 41: 489–96
- Cordonnier C., Vernant J.P., Brun B., Heilmann M.G., Kuentz M., Bierling P., Farcet J.P., Rodet M., Duedari N., Imbert M., Jouault H., Mannoni P., Reyes F., Dreyfus B., Rochant H. Acute promyelocytic leukemia in 57 previously untreated patients. Cancer 1985; 55: 18–25
- Kantarjian H.M., Keating M.J., Walters R.S., Estey E.H., McCredie K.B., Smith T.L., Dalton W.T., Jr., Cork A., Trujillo J.M., Freireich E.H. Acute promyelocytic leukemia: The MD Anderson Hospital experience. Am. J. Med. 1986; 80: 789–97
- Sanz M.A., Jarque I., Martin G., Lorenzo I., Martinez J., Rafecas J., Pastor E., Sayas M.J., Sanz G., Gomis F. Acute promyelocytic leukemia: Therapy results and prognostic factors. Cancer 1988; 61: 7–13
- Cunningham I., Gee T.S., Reich L.M., Kempin S.J., Naval A.N., Clarkson B.D. Acute promyelocytic leukemia: Treatment results during a decade at Memorial Hospital. Blood 1989; 73: 1116–22
- Pallavicini E.B., Porta C., Anselmetti L., Viarengo G.L., Nastasi G., Notario A. Acute promyelocytic leukaemia (APL): Chemotherapy or bone marrow transplantation?. Bone Marrow Transplant. 1989; 4: 102, Suppl. 3
- Runde V., Aul C., Landen H., Dokekias A., Fillet G., Schneider W. Acute promyelocytic leukemia: Clinical findings and therapeutic results in 30 patients. Hamatol. Bluttransfus. 1990; 33: 346–50
- Bennett J.M., Andersen J.W., Cassileth P.A. Long term survival in acute myeloid leukemia: The Eastern Cooperative Oncology Group (ECOG) experience. Leuk. Res. 1991; 15: 223–7
- Fenaux P., Tertian G., Castaigne S., Tilly H., Leverger G., Guy H., Bordessoule D., Lebley R., LeGall E., Colombat P., Tchemia F., Bauters F., Marty M. A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia. J. Clin. Oncol 1991; 9: 1556–61
- Head D.R., Kopecky K., Hewlett J., Weick J., Ryan D., Files J., Bickers J., Foucar K., Montiel M., Fishleder A., Welborn J., Mills G., Billeter E., Willman C., Appelbaum F. Survival with cytotoxic therapy in acute promyelocytic leukemia, a SWOG report. Blood 1991; 78: 268a, Suppl. 1
- Huang M., Ye Y., Chen S., Chai J., Lu J.-X., Zhoa L., Gu L., Wang Z. Use of all trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–72
- Warrell R.P., Jr., Frankel S.R., Miller W.H., Jr., Scheinberg D.A., Itri L.M., Hittelman W.N., Vyas R., Andreeff M., Tafuri A., Jakubowski A., Gabrilove J., Gordon M.S., Dmitrovsky E. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N. Engl. J. Med. 1991; 324: 1385–93
- Fenaux P., Castaigne S., Dombret H., Archimbaud E., Duarte M., Morel P., Lamy T., Tilly H., Guerci A., Maloisel F., Bordessoule D., Sadoun A., Tiberghien P., Fegueux N., Daniel M.T., Chomienne C., Degos L. All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: A pilot study on 26 cases. Blood 1992; 80: 2176–81
- Clift R.A., Buckner C.D., Thomas E.D., Kopecky K.J., Appelbaum F.R., Tallman M., Storb R., Sanders J., Sullivan K., Banaji M., Beatty P.S., Bensinger W., Cheever M., Deeg J., Doney K., Fefer A., Greenberg P., Hansen J.A., Hackman R., Hill R., Martin P., Meyers J., McGuffin R., Neiman P., Sale G., Shulman H., Singer J., Stewart P., Weiden P., Witherspoon R. The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant. 1987; 2: 243–58
- Bennett J.M., Catovsky D., Daniel M.-T., Flandrin G., Gallon D.A.G., Gralnick H.R., Sultan C. Proposals for the classification of the acute leukaemias. Br. J. Haematol. 1976; 33: 451–8
- Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A.G., Gralnick H.R., Sultan C. A variant form of hypergranular promyelocytic leukaemia(M3). Br. J. Haematol. 1980; 44: 169–70
- Golomb H.M., Rowley J.D., Vardiman J.W., Testa J.R., Butler A. “Microgranular” acute promyelocytic leukemia: A distinct clinical, ultrastructural, and cytogenetic entity. Blood 1980; 55: 253–9
- ISCN. “Guidelines for Cancer Cytogenetics, Supplement to An International System for Human Cytogenetic Nomenclature.”, F Mitelman. S Karger, Basel 1991, 1991
- Cheson B.D., Cassileth P.A., Head D.R., Schiffer C.A., Bennett J.M., Bloomfield C.D., Brunning R., Gale R.P., Grever M.R., Keating M.J., Sawitsky A., Stass S., Weinstein H., Woods W.G. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J. Clin. Oncol. 1990; 8: 813–9
- Reece D.E., Barnett M., Bow E., Klingemann H.-G., Shepherd J., Shore T., Phillips G. High dose cytosine arabinoside (HD Ara-C), etoposide (VP-16) and daunorubicin (DNR) as initial induction and consolidation therapy for adult acute myelogenous leukemia (AML). Blood 1990; 76: 312a, Suppl. 1
- Tutschka P.J., Copelan E.A., Klein J.P. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382–8
- Storb R., Deeg H.J., Pepe M., Appelbaum F., Anasetti C., Beatty P., Bensinger W., Berenson R., Buckner C.D., Clift R., Doney K., Longton G., Hansen J., Hill R., Loughran T., Jr., Martin P., Singer J., Sanders J., Stewart P., Sullivan K., Witherspoon R., Thomas E.D. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial. Blood 1989; 73: 1729–34
- Elmongy M.B., Nantel S.H., Reece D.E., Barnett M.J., Shepherd J.D., Klingemann H.-G., Sutherland H., Embree L., Phillips G.L. Autologous bone marrow transplantation (BMT) for acute myeloid leukemia (AML) using combined carboplatin (CBDCA) and busulfan (BU). A phase I/II study. Proc. Am. Soc. Clin. Oncol. 1993; 12: 312
- Yeager A.M., Kaizer H., Santos G.W., Saral R., Colvin O.M., Stuart R.K., Braine H.G., Burke P.J., Ambinder R.F., Burns W.H., Fuller D.J., Davis J.M., Karp J.E., May W.S., Rowley S.D., Sensenbrenner L.L., Vogelsang G.B., Wingard J.R. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N. Engl. J. Med. 1986; 315: 141–7
- Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc 1958; 53: 457–81
- Clift R.A., Buckner C.D., Appelbaum F.R., Schoch G., Petersen F.B., Bensinger W.I., Sanders J., Sullivan K.M., Storb R., Singer J., Hansen J.A., Thomas E.D. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J. Clin. Oncol. 1992; 10: 1723–9
- Linker C.A., Ries C.A., Damon L.E., Rugo H.S., Wolf J.L. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood 1993; 81: 311–8
- Frankel S.R., Eardley A., Lauwers G., Weiss M., Warrell R.P., Jr. The “retinoic acid syndrome” in acute promyelocytic leukemia. Ann. Intern. Med. 1992; 117: 292–6
- Fenaux P., LeDeley M.C., Castaigne S., Archimbaud E., Chomienne C., Link H., Guerci A., Duarte M., Daniel M.T., Bowen D., Huebner G., Bauters F., Fegueux N., Fey M., Sans M., Lowenberg B., Maloisel F., Auzanneau G., Sadoun A., Gardin C., Bastion Y., Ganser A., Jacky E., Dombret H., Chastang C., Degos L., the European A PL 91 Group. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood 1993; 82: 3241–9